Clinical trial · Interventional
Radiation Therapy Approaches for People With Prostate Cancer
Balancing Radiation Intensification and Quality of Life in Higher-Risk Prostate Cancer (The BALANCE-RT Trial)
NCT07751159CI-TRIAL-00121774recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to explore the best ways of giving radiation therapy to balance cancer control and treatment side effects.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| High Risk Prostate Cancer | — | UNRESOLVED | — |
| Non-metastatic Prostate Cancer | — | UNRESOLVED | — |
| Prostate Cancer Patients | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SBRT | Radiation | — | UNRESOLVED |
| Standard of Care HDR Brachytherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Arm A: HDR Brachytherapy Boost + SBRT
- description
- Standard of Care Brachytherapy/Radiation and SBRT
- interventionNames
- Radiation: Standard of Care HDR Brachytherapy
- Radiation: SBRT
- type
- EXPERIMENTAL
- label
- Arm B: SBRT Alone
- description
- SBRT alone
- interventionNames
- Radiation: SBRT
Primary outcomes (1)
- measure
- Change in International Prostate Symptom Score / IPSS at 3 months
- timeFrame
- 3 months
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Non-metastatic prostate cancer. * Classified as unfavorable intermediate-, high-, or very high-risk prostate cancer according to NCCN risk stratification guidelines. (Note: cT3a or T3b by MRI or PSMA PET allowed) * Considered by the treating radiation oncologist as a suitable candidate for both HDR brachytherapy boost and SBRT Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.